nach oben

Rheumatology International

Erschienen in:

01.11.2014 | Review Article

Network meta-analysis for comparing treatment effects of multiple interventions: an introduction

verfasst von: Ferrán Catalá-López, Aurelio Tobías, Chris Cameron, David Moher, Brian Hutton

Erschienen in: Rheumatology International | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Systematic reviews and meta-analyses of randomized trials have long been important synthesis tools for guiding evidence-based medicine. More recently, network meta-analyses, an extension of traditional meta-analyses enabling the comparison of multiple interventions, use new statistical methods to incorporate clinical evidence from both direct and indirect treatment comparisons in a network of treatments and associated trials. There is a need to provide education to ensure that core methodological considerations underlying network meta-analyses are well understood by readers and researchers to maximize their ability to appropriately interpret findings and appraise validity. Network meta-analyses are highly informative for assessing the comparative effects of multiple competing interventions in clinical practice and are a valuable tool for health technology assessment and comparative effectiveness research.

Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269PubMedCrossRef

Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897–900PubMedCrossRefPubMedCentral

Salanti G (2012) Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3:80–97CrossRef

Ioannidis JP (2009) Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 181:488–493PubMedCrossRefPubMedCentral

Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH (2012) How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 308:1246–1253PubMedCrossRef

Mills EJ, Thorlund K, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914PubMedCrossRef

Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159:130–137PubMedCrossRef

Higgins JP, Whitehead A (1996) Borrowing strength from external trials in a meta-analysis. Stat Med 15:2733–2749PubMedCrossRef

10.

Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691PubMedCrossRef

11.

Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21:2313–2324PubMedCrossRef

12.

Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105–3124PubMedCrossRef

13.

Salanti G, Kavvoura FK, Ioannidis JP (2008) Exploring the geometry of treatment networks. Ann Intern Med 148:544–553PubMedCrossRef

14.

Catalá-López F, Hutton B, Moher D (2014) The transitivity property across randomized controlled trials: if B is better than A, and C is better than B, will C be better than A? Rev Esp Cardiol. doi:10.1016/j.recesp.2013.11.016

15.

Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ et al (2011) Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 343:d4909PubMedCrossRefPubMedCentral

16.

Jansen JP, Naci H (2013) Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 11:159PubMedCrossRefPubMedCentral

17.

Trinquart L, Abbé A, Ravaud P (2012) Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials. PLoS One 7:e35219PubMedCrossRefPubMedCentral

18.

Trinquart L, Chatellier G, Ravaud P (2012) Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol 12:150PubMedCrossRefPubMedCentral

19.

Mills EJ, Kanters S, Thorlund K, Chaimani A, Veroniki AA, Ioannidis JP (2013) The effects of excluding treatments from network meta-analyses: survey. BMJ 347:f5195PubMedCrossRefPubMedCentral

20.

Salanti G, Marinho V, Higgins JP (2009) A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 62:857–864PubMedCrossRef

21.

Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171PubMedCrossRef

22.

Bafeta A, Trinquart L, Seror R, Ravaud P (2013) Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. BMJ 347:f3675PubMedCrossRefPubMedCentral

23.

Lee AW (2014) Review of mixed treatment comparisons in published systematic reviews shows marked increase since 2009. J Clin Epidemiol 67:138–143PubMedCrossRef

24.

Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A (2012) Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 6:429–464PubMedPubMedCentral

25.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al (2009) A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a cochrane overview. CMAJ 181:787–796. Erratum in: CMAJ 2010 182(8):806

26.

Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39:425–441PubMedCrossRef

27.

Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B et al (2011) Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 38:835–845PubMedCrossRef

28.

Turkstra E, Ng SK, Scuffham PA (2011) A mixed treatment comparison of the short term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin 27:1885–1897PubMedCrossRef

29.

Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O (2012) A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis 71:225–230PubMedCrossRef

30.

Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV et al (2011) Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev 2:CD008794

31.

Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE (2013) Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak 33:641–656CrossRef

32.

Dias S, Sutton AJ, Welton NJ, Ades AE (2013) Evidence synthesis for decision making 3: heterogeneity–subgroups, meta-regression, bias, and bias-adjustment. Med Decis Mak 33:618–640CrossRef

33.

Dias S, Sutton AJ, Ades AE, Welton NJ (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak 33:607–617CrossRef

34.

Dias S, Welton NJ, Sutton AJ, Ades AE (2013) Evidence synthesis for decision making 1: introduction. Med Decis Mak 33:597–606CrossRef

35.

Li T, Puhan MA, Vedula SS, Singh S, Dickersin K, Ad hoc network meta-analysis methods meeting working group (2011) Network meta-analysis-highly attractive but more methodological research is needed. BMC Med 9:79PubMedCrossRefPubMedCentral

36.

Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ (2013) Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol 9:665–673PubMedCrossRef

37.

Thorlund K, Druyts E, Aviña-Zubieta JA, Wu P, Mills EJ (2013) Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 72:1524–1535PubMedCrossRef

38.

Ades AE, Madan J, Welton NJ (2011) Indirect and mixed treatment comparisons in arthritis research. Rheumatology (Oxford) 50(suppl 4):iv5–iv9CrossRef

39.

Ades AE, Caldwell DM, Reken S, Welton NJ, Sutton AJ, Dias S (2013) Evidence synthesis for decision making 7: a reviewer’s checklist. Med Decis Mak 33:679–691CrossRef

40.

Nikolakopoulou A, Chaimani A, Veroniki AA, Vasiliadis HS, Schmid CH, Salanti G (2014) Characteristics of networks of interventions: a description of a database of 186 published networks. PLoS One 9:e86754PubMedCrossRefPubMedCentral

41.

Sutton AJ, Abrams KR (2001) Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 10:277–303PubMedCrossRef

Titel: Network meta-analysis for comparing treatment effects of multiple interventions: an introduction
verfasst von: Ferrán Catalá-López
Aurelio Tobías
Chris Cameron
David Moher
Brian Hutton
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 11/2014
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-014-2994-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndrome

Establishing hospital admission criteria of pediatric Henoch–Schonlein purpura

Fibromyalgia and non-celiac gluten sensitivity: a description with remission of fibromyalgia

Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip

Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis